Phenytoin-induced alterations in craniofacial gene expression.
In utero exposure to the anticonvulsant drug phenytoin has been shown to alter normal embryonic development, leading to a pattern of dysmorphogenesis known as the Fetal Hydantoin Syndrome. This embryopathy is characterized by growth retardation, microcephaly, mental deficiency, and craniofacial malformations, although the precise mechanism(s) by which phenytoin alters normal developmental pathways remains unknown. To better understand the molecular events involved in the pathogenesis of phenytoin-induced congenital defects, alterations in gene expression were examined during critical periods of craniofacial development. Pregnant SWV mice were administered phenytoin (60 mg/kg/day) from gestational day 6.5 until they were sacrificed at selected developmental time points. Tissue from the craniofacial region of control and exposed embryos was isolated, and samples were subjected to in situ transcription, antisense RNA amplification, and hybridization on reverse Northern blots to quantitatively assess expression of 36 candidate genes. Chronic phenytoin exposure significantly altered expression of several genes at distinct times during morphogenesis. Results of these studies show that expression of the retinoic acid receptors (RAR) alpha, beta, and gamma were significantly increased by phenytoin exposure. Elevations in gene expression of laminin beta 1, and the growth factors IGF-2, TGF alpha, and TGF beta 1, were also demonstrated in the craniofacial region of phenytoin-exposed embryos. As several of these genes are transcriptionally regulated by retinoic-acid-responsive elements in their promoter regions, phenytoin-induced alterations in expression of the RAR isoforms may have severe downstream consequences in the regulation of events necessary for normal craniofacial development. Such alterations occurring coordinately at critical times during craniofacial development may account for the dysmorphogenesis often associated with phenytoin exposure.
Gelineau-van Waes
J
J
Department of Veterinary Anatomy and Public Health, Texas A&M University, College Station 77843-4458, USA.
Bennett
G D
GD
Finnell
R H
RH
D000014:Abnormalities, Drug-Induced / Q000235:genetics; D000818:Animals; D000927:Anticonvulsants / Q000633:toxicity*; D018076:DNA, Complementary; D005314:Embryonic and Fetal Development / Q000187:drug effects; D005145:Face / Q000196:embryology; D005260:Female; D015870:Gene Expression / Q000187:drug effects*; D051379:Mice; D008815:Mice, Inbred Strains; D009024:Morphogenesis; D010672:Phenytoin / Q000633:toxicity*; D011247:Pregnancy; D018168:Receptors, Retinoic Acid / Q000235:genetics; D012886:Skull / Q000196:embryology